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Articles
PATIENTS AND BIOBANKS
ELLEN WRIGHT CLAYTON*
NTIL recently, I usually saw patients in either our walk-in clinic or
the hospital without access to their old charts. Given the nature of
general pediatric practice in a teaching hospital like ours, I often did not
know before I walked in the room whether the "five-year-old with fever"
was a normal kindergartener who had entered school for the first time
and was catching the obligatory viruses or a child with multiple medical
problems who was taking numerous medications, not all of which were
fully remembered or understood by the person who brought the child. In
either event, the child's prior chart might not appear until after the child
had been sent home, if then. Things, of course, were not quite that bad;
most of the children with chronic problems were well known to the clinic
personnel, but still, gaps remained.
Things are different now. When a child comes in today, the person
who is going to see the child, whether a student, resident or faculty, first
sits down at a computer, which provides immediate access to the child's
past medical history and laboratory and radiologic evaluations. Most of
these entries are actually legible,' which is another bonus.
While the electronic medical record (EMR) is generally a huge help,
it is a mixed blessing. Knowing a lot before you walk in the door narrows
your focus, perhaps causing you to miss something that you would have
seen with a more open mind. Computer screens, which are present in
many of our examining rooms, enable the care team-care technicians,
nurses and physicians-to enter data directly into the medical record.
This efficiency, however, comes at some cost: the care provider either
must sit with his or her back to the patient to enter data or the computer
screen is interposed between them. The presence of the computer is a
visible reminder of the reality that health information is not confined to
the examining room. Nor can technology guarantee accuracy. Some-
times, as much as we hate to admit it, mistakes and even misdiagnoses
creep into the record, which can lead to confusion for the care provider.
While mistakes always have been present in medical records, the "cut and
paste" aspects of the EMR can actually increase errors.2 But the most im-
* Ellen Wright Clayton, M.D., J.D., is the Rosalind E. Franklin Professor of
Genetics and Health Policy, Professor of Pediatrics, Professor of Law and Co-
Director of the Center for Biomedical Ethics and Society at Vanderbilt University.
1. Some of the entries are scanned handwritten clinic notes.
2. This is particularly true for the history and physical examination, which
necessarily depend on the personal recollection and observation of the person
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portant aspect of this technology for the present discussion is that its ac-
cessibility is its greatest liability as well as its greatest strength.
The question about the privacy of medical information can be stated
simply: To what extent can and should patients control what the medical
record contains and who has access to it and for what purposes? 3 Patients
often have apparently conflicting views on this subject. On the one hand,
we, as patients, say that we prize privacy and that we fear that information
will be used to harm us. On the other hand, we value the benefits that
come from improved communication among providers, such as having
our visits covered by third party payers and advances in medical science,
which often come from researchers and providers having access to large
data sets. These apparently contradictory desires are not unique to health
care. In many other arenas of life, we sell information about ourselves
incredibly cheaply, as the grocery and drug store discount tags on our key
chains attest. But areas of discomfort remain, one of which I will explore:
the use of the contents of the electronic record for medical research.
Evolving practices in this area raise a host of questions.
The EMR has the potential to be a godsend for research and for mini-
mizing the risk that others would have access to identified health informa-
tion. In the past, information had to be abstracted by hand, a labor-
intensive process requiring an investigator to examine each page, necessa-
rily compromising the patient's privacy. Although the initial invasion
could not be avoided, researchers could try to mask identifying informa-
tion prior to photocopying or record subsets of non-specified data on sep-
arate forms. Given the burdensomeness of this process, it was often
tempting to capture as much information as possible on the first pass, par-
ticularly because there often was no opportunity or desire to undertake
the onerous task of examining records again at a later time to update the
research files. Sometimes, patients were asked to consent to this type of
research, but at other times, institutional review boards (IRBs) considered
such projects to be exempt from the regulations for the protection of
human subjects so long as identifiers were removed from the final data set.
With the EMR, it is possible to limit one's search to specified fields.
The resulting data sets can be encrypted to protect privacy even further.4
who initially puts them in the medical record. These can then be copied by other
providers and adopted as their own. See Interview with Daniel Masys, Professor and
Chair, Dep't of Biomedical Informatics, Vanderbilt Univ. Med. Ctr., in Nashville,
Tenn. (Oct. 18, 2005). On the other hand, the ability to copy laboratory values
and radiology reports directly into progress notes clearly improves accuracy.
3. Confidentiality refers to the obligations of those who hold information to
respect the privacy interests of those which the data relate. Security refers to safe-
guards or tools, both technical and administrative, to protect health data from
access or disclosure. SeeJames G. Hodge, Jr. et al., Legal Issues Concerning Electronic
Health Information, 282 JAMA 1466, 1466-68 (1999).
4. Bradley Malin & Latanya Sweeney, Determining the Identifiability of DNA
Database Entries, PROC., J. Am. MED. INFORMATIcs Ass'N 537, 538 (2002); Latanya
Sweeney, Weaving Technology and Policy Together to Maintain Confidentiality, 25 J.L.
MED. & ETHICS 98, 102-07 (1997).
[Vol. 51: p. 793
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It is typically easy, for example, to correlate hypertension with levels of
serum creatinine in a large population, and this can be done without hav-
ing a human eye look at the entire record or even at a particular patient's
name. And now that we are in the genomics era, investigators would like
to combine this clinical data with studies of DNA to create so-called "bi-
obanks" to examine how genetic variation contributes to disease.
In this Essay, I will demonstrate that current regulations in the United
States for the protection of human subjects and of informational privacy
permit research using the EMR and biological specimens5 collected in the
course of clinical care 6 to be conducted without consent of the patients to
whom they relate, or even IRB without review. Despite this regulatory gap,
many institutions are developing elaborate systems for oversight and, in
many cases, obtaining consent or at least providing greater transparency, a
phenomenon I will explore in the conclusion.
The two bodies of law most relevant here are the regulations for the
protection of human subjects, usually referred to as the "Common Rule,"7
and the privacy regulations promulgated under the Health Insurance
Portability and Accountability Act (HIPAA). 8 The Common Rule exempts
from its coverage the study of existing information and samples "recorded
by the investigator in such a manner that subjects cannot be identified,
directly or through identifiers linked to the subjects."9 It then goes on to
define "human subject" as:
[A] living individual about whom an investigator (whether pro-
fessional or student) conducting research obtains... (2) Identifi-
able private information. . . . Private information includes
information about behavior that occurs in a context in which an
individual can reasonably expect that no observation or record-
ing is taking place, and information which has been provided for
specific purposes by an individual and which the individual can
reasonably expect will not be made public (for example, a medi-
cal record). Private information must be individually identifiable
5. DNA can be obtained from virtually any biological sample. Laboratory
tests for adults typically call for between five to ten milliliters of blood. Modern
technologies usually require only a small portion of that amount. The white cells
contained in the remaining sample are rich sources of DNA. Modern methods of
DNA amplification make it possible to obtain DNA even from urine, which in the
absence of acute infection or other disease, contain very few cells at all.
6. It is important to distinguish the use of information and samples explicitly
collected for purposes of research. The big questions in this context are whether
investigators can use these data for other types of research and whether research
participants can give valid consent for future unspecified research uses. These are
vexed issues in their own right, but at least the research participants are aware that
they are involved in some sort of research, which often is not true for patients
seeking clinical care.
7. Common Rule, 45 C.F.R. § 46 (2005).
8. Id. §§ 160, 164.
9. Id. § 46.101 (b) (4).
2006]
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(i.e., the identity of the subject is or may readily be ascertained by
the investigator or associated with the information) in order for
obtaining the information to constitute research involving
human subjects. 10
In 2004, the Office of Human Research Protections (OHRP) discussed
this definition in a guidance document which stated that:
OHRP does not consider research involving only coded private
information or specimens to involve human subjects as defined
under 45 CFR 46.102(f) if the following conditions are both met:
(1) the private information or specimens were not collected
specifically for the currently proposed research project
through an interaction or intervention with living individu-
als; and
(2) the investigator(s) cannot readily ascertain the identity
of the individual(s) to whom the coded private information
or specimens pertain because, for example:
(a) the key to decipher the code is destroyed before the
research begins;
(b) the investigators and the holder of the key enter
into an agreement prohibiting the release of the key to
the investigators under any circumstances, until the in-
dividuals are deceased (note that the HHS regulations
do not require the IRB to review and approve this
agreement);
(c) there are IRB-approved written policies and operat-
ing procedures for a repository or data management
center that prohibit the release of the key to the investi-
gators under any circumstances, until the individuals
are deceased; or
(d) there are other legal requirements prohibiting the
release of the key to the investigators, until the individu-
als are deceased.
This guidance applies to existing private information and speci-
mens, as well as to private information and specimens to be col-
lected in the future for purposes other than the currently
proposed research. The following are examples of private infor-
mation or specimens that will be collected in the future for pur-
poses other than the currently proposed research: (1) medical
records, and (2) ongoing collection of specimens for a tissue
repository. 11
10. Id. § 46.102(f).
11. OFFICE FOR HUMAN RESEARCH PROTS., DEP'T OF HEALTH & HUMAN SERVS.,
GUIDANCE ON RESEARCH INVOLVING CODED PRIVATE INFORMATION OR BIOLOGICAL
[Vol. 51: p. 793
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This makes clear that, so long as they are coded appropriately, all informa-
tion and tissue collected for purposes of clinical care can be used for re-
search without being considered to involve human subjects and hence
would not be subject to the Common Rule.
The HIPAA privacy regulations, or the "Privacy Rule," take a different
approach focusing on de-identification, which can be accomplished either
by statistically approved methods or by removing eighteen specific identifi-
ers. 12 Notably, categories such as race, ethnicity and socioeconomic status
SPECIMENS (2004), available at http://www.hhs.gov/ohrp/humansubjects/gui-
dance/cdebiol.pdf [hereinafter OHRP GUIDANCE DOCUMENT].
12. Information is de-identified if:
(1) A person with appropriate knowledge of and experience with gener-
ally accepted statistical and scientific principles and methods for render-
ing information not individually identifiable: ...
(i) Applying such principles and methods, determines that the risk is very
small that the information could be used, alone or in combination with
other reasonably available information, by an anticipated recipient to
identify an individual who is a subject of the information; ...
(2) (i) The following identifiers . . . are removed:
(A) Names;
(B) All geographic subdivisions smaller than a State, including street ad-
dress, city, county, precinct, zip code, and their equivalent geocodes, ex-
cept for the initial three digits of a zip code if, according to the current
publicly available data from the Bureau of the Census:
(1) The geographic unit formed by combining all zip codes with the same
three initial digits contains more than 20,000 people; and
(2) The initial three digits of a zip code for all such geographic units
containing 20,000 or fewer people is changed to 000.
(C) All elements of dates (except year) for dates directly related to an
individual, including birth date, admission date, discharge date, date of
death; and all ages over 89 and all elements of dates (including year)
indicative of such age, except that such ages and elements may be aggre-
gated into a single category of age 90 or older;
(D) Telephone numbers;
(E) Fax numbers;
(F) Electronic mail addresses;
(G) Social security numbers;
(H) Medical record numbers;
(I) Health plan beneficiary numbers;(J) Account numbers;
(K) Certificate/license numbers;
(L) Vehicle identifiers and serial numbers, including license plate
numbers;
(M) Device identifiers and serial numbers;
(N) Web Universal Resource Locators (URLs);
(0) Internet Protocol (IP) address numbers;
(P) Biometric identifiers, including finger and voice prints;
(Q) Full face photographic images and any comparable images; and
(R) Any other unique identifying number, characteristic, or code.. .
and
(ii) The covered entity does not have actual knowledge that the informa-
tion could be used alone or in combination with other information to
identify an individual who is a subject of the information.
45 C.F.R. § 164.514(b).
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are not among the identifiers that must be removed to comply with HIPAA
standards. Coded information can be considered to be de-identified for
purposes of HIPAA so long as the investigator does not have the key and
so long as the code is not itself based on personal health information
(PHI). In addition, the Privacy Rule expressly excludes three types of in-
vestigations from its coverage: studies done in preparation for research, so
long as the PHI is not removed from the institution and is necessary to
develop the protocol; studies involving decedents, so long as living individ-
uals will not be investigated; 13 and research involving "limited data sets,"
defined as those from which sixteen of the eighteen identifiers have been
removed, so long as the investigators execute a data use agreement. 14
Although the provisions of these two regulatory schemes do not com-
pletely coincide, there nonetheless exists a large space in which it would
be possible to create a biobank of clinical information and DNA sequences
from leftover biological specimens that could support a wide array of re-
search of epidemiologic and genetic variation research but would not be
covered by either the Common Rule or the HIPAA Privacy Rule. Within
this gap, neither the informed consent requirements of the former nor
the authorization requirements of the latter would apply. No particular
form of oversight would be required either. OHRP recognized that proto-
cols involving such datasets would not be subject to IRB review under their
guidance. They recommended instead that institutions identify someone
"to determine whether research involving coded private information or
specimens constitutes human subjects research" and that such a determi-
nation not be left solely to investigators themselves. 15
Because our laws permit the research use of these large aggregations
of clinical and genetic information without oversight or consent, should
we care? After identifiers are removed, do any privacy interests remain to
be invaded? If the answer is yes, has the polity chosen to override those
interests for the public good? After all, laws reflect our collective will.
And yet, reasons for disquiet remain. While the Common Rule has
for years permitted a great deal of epidemiologic research to be con-
ducted without individual consent, the power of current approaches vastly
exceeds what was possible when that rule was initially adopted, now almost
a quarter century ago. Some people find it disturbing that the institutions
from which they seek health care are using information about them1 6 or
13. Id. § 164.512(i).
14. Id. § 164.514(e)(1).
15. OHRP GUIDNCE DOCUMENT, supra note 11, at 4.
16. The literature on this issue is quite complex. A number of investigators
have explored patients' opinions about the use of clinical information for re-
search. In general, all have found that a substantial percentage of patients have
concerns, particularly about research conducted without specific consent. See
Richard Baker et al., What Proportion of Patients Refuse Consent to Data Collection from
Their Records for Research Purposes?, 50 BRIT. J. GEN. PRAc. 655, 655-56 (2000);
Kalpana Nair et al., Patients' Consent Preferences Regarding the Use of Their Health Infor-
mation for Research Purposes: A Qualitative Study, 9 J. HEALTH SERVS. REs. & POL'y 22,
[Vol. 51: p. 793
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residual biological samples 17 not only to help them but also to conduct
22-27 (2004); M.R. Robling et al., Public Attitudes Towards the Use of Primary Care
Patient Record Data in Medical Research Without Consent: A Qualitative Study, 30 J. MED.
ETHICS 104, 104-09 (2004); Richard Whiddett et al., Patients'Attitudes Towards Shar-
ing Their Health Information, INT'LJ. MED. INFORMATICS (forthcoming 2006); Donald
J. Willison et al., Patients' Consent Preferences for Research Uses of Information in Elec-
tronic Medical Records: Interview and Survey Data, 326 BRIT. MED. J. 373, 373-80
(2003). One more in-depth study revealed that most patients were comfortable
with use of their clinical information without consent if they were convinced that
access was limited to authorized personnel and that security measures actually
worked. See Nancy E. Kass et al., The Use of Medical Records in Research: What Do
Patients Want?, 31 J.L. MED. ETHICS 429, 429-33 (2003).
17. Spurred by recent developments in genomics that make it possible to ob-
tain information from residual biological specimens, public opinion surveys re-
garding the use of tissue samples for research have been conducted in numerous
parts of the world. Not surprisingly, they show quite disparate results. People in
Sweden, for example, are quite favorably disposed toward research using linked
tissue samples. Klaus Hoeyer et al., Informed Consent and Biobanks: A Population-
Based Study of Attitudes Towards Tissue Donation for Genetic Research, 32 SCANDANAVIAN
J. PUB. HEALTH 224, 224-29 (2004); Asa Kettis-Lindblad et al., Genetic Research and
Donation of Tissue Samples to Biobanks. What Do Potential Sample Donors in the Swedish
GeneralPublic Think?, EUR.J. PUB. HEALTH (forthcoming 2006). Although a major-
ity thought that specific consent should be required to examine medical records, a
similar number was willing to defer to permission given by an ethics committee.
Despite this widespread public approval, Sweden nonetheless passed a law requir-
ing that patients provide informed consent before samples can be used for re-
search. See Karolinska Institutet, Biobank, Frequently Asked Questions, http://
www.meb.ki.se/biobank/faq.php (last visited Feb. 9, 2006).
For interviewees in the United States, see Marc D. Schwartz et al., Consent to the
Use of Stored DNA for Genetics Research: A Survey of Attitudes in the Jewish Population, 98
Am.J. MED. GENETICS 336, 338 (2001) (stating that majority believe informed con-
sent is required); Sophia S. Wang et al., Public Attitudes Regarding the Donation and
Storage of Blood Specimens for Genetic Research, 4 COMMUNITY GENETICS 18, 20 (2001)
(noting twenty-one percent unalterably opposed); Dave Wendler & Ezekiel Eman-
uel, The Debate over Research on Stored Biological Samples: What Do Sources Think?, 162
ARCHIVES INTERNAL MED. 1457, 1457 (2002) (stating that respondents more likely
to want to require informed consent for clinical samples than research samples).
Interviewees in the United Kingdom and other countries were more cautious
about permitting clinical samples to be used for research, particularly without con-
sent. See, e.g., M.L. Goodson & B. G. Vernon, A Study of Public Opinion on the Use of
Tissue Samples from Living Subjects for Clinical Research, 57 J. CLINICAL PATHOLOGY
135, 135 (2004) (noting eighteen percent would not agree to research use at all);
see also Atsushi Asai et al., Attitudes of the Japanese Public and Doctors Towards Use of
Archived Information and Samples Without Informed Consent: Preliminary Findings Based
on Focus Group Interviews, 3 BMC MED. ETHICS 1, 1-10 (2002); K. Matsui et al., In-
formed Consent, Participation in, and Withdrawal from a Population Based Cohort Study
Involving Genetic Analysis, 31 J. MED. ETHICS 385 (2005); Wong Mee Lian et al.,
Willingness to Donate Blood Samples for Genetic Research: A Survey from a Community in
Singapore, 65 CLINICAL GENETICS 45, 45-51 (2004).
By contrast, people who were already enrolled in studies were often quite
likely to agree to have their tissues and information used for future research.
Donna T. Chen et al., Research with Stored Biological Samples: What Do Research Partici-
pants Want?, 165 ARCHIVES INTERNAL MED. 652, 652-55 (2005); Thomas Malone et
al., High Rate of Consent to Bank Biologic Samples for Future Research: The Eastern Cooper-
ative Oncology Group Experience, 94J. NAT'L CANCER INST. 769 (2002); Geraldine M.
McQuillan et al., Consent for Genetic Research in a General Population: The NHANES
Experience, 5 GENETICS MED. 35 (2003); Birgitta Stegmayr & Kjell Asplund, Informed
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research, especially without their consent. Many people worry about seek-
ing health care for fear that they will be used as "guinea pigs." To be sure,
most of these fears reflect concerns that they will be subjected to experi-
mental medications or surgeries,18 or that they will be cared for by learn-
ers in the context of academic medical centers, but the fine points of
biobanks may fail to persuade those who already distrust the health care
system. More to the point, these regulations identify a large hole in the
legally protected control individuals have over information regarding their
health and in the oversight of research.
Interestingly, even though the law does not always require it,19 many
institutions are seeking informed consent and putting in place mecha-
nisms for oversight of biobanks. Some IRBs are reviewing biobanks at
their own institutions and the ways they are used even when those projects
are structured to be technically exempt under current OHRP guidance
and HIPAA regulations.20 Even though some commentators urge that
seeking consent creates bias or is unnecessary,2 many institutions still ob-
tain consent. The Marshfield Clinic, for example, engaged in an elaborate
process of public education2 2 and consultation and sought informed con-
Consent for Genetic Research on Blood Stored for More Than a Decade: A Population Based
Study, 325 BRIT. MED. J. 634 (2002).
18. See L. Ebony Boulware et al., Race and Trust in the Health Care System, 118
PUB. HEALTH REP. 358 (2003).
19. It is more difficult to ascertain how many institutions are taking advantage
of the haven created by the Office of Human Research Protections (OHRP) gui-
dance and Health Insurance Portability and Accountability Act (HIPAA)
exclusions.
20. See, e.g., Mary Terrell White &Jennifer Gamm, Informed Consent for Research
on Stored Blood and Tissue Samples: A Survey of Institutional Review Board Practices, 9
ACCOUNTABILITY RES. 1, 1-16 (2002) (noting that practices were quite variable).
The IRB at Vanderbilt University Medical Center has exercised a great deal of
oversight over the DNA databank that is being developed.
21. Steven J. Jacobsen et al., Potential Effect of Authorization Bias on Medical Re-
cord Research, 74 MAYO CLINIC PROC. 330, 330-38 (1999); Steven H. Woolf et al.,
Selection Bias from Requiring Patients to Give Consent to Examine Data for Health Services
Research, 9 ARCHVEs FAM. MED. 1111, 1115-17 (2000); Barbara P. Yawn et al., The
Impact of Requiring Patient Authorization for Use of Data in Medical Records Research, 47
J. FAM. PRAc. 361, 361-65 (1998); cf. Eike-Henner W. Kluge, Informed Consent to the
Secondary Use of EHRs: Informatic Rights and Their Limitations, 11 MEDINFO 635, 635-
38 (2004) (stating that informed consent should nonetheless be obtained where
possible).
22. Other institutions have also chosen to publicize their efforts to create bi-
obanks in local papers and in-house media. See Gareth Cook, Harvard Project to
Scan Millions of Medical Files, BOSTON GLOBE, July 3, 2005, at Al; Leigh MacMillan,
New Databank to Be a Trove of Anonymous DNA Information, REPORTER (Vanderbilt
Med. Ctr.), July 22, 2005, at 1, available at http://www.mc.vanderbilt.edu/re-
porter/index.html?ID=4103; Leigh MacMillan, VUMC's DNA Databank Discussed at
Ethics Meet, REPORTER (Vanderbilt Med. Ctr.), Nov. 4, 2005, at 1, available at http://
www.mc.vanderbilt.edu/reporter/index.html?ID=4353; Shannon Pettypiece, Case,
Clinic Casting Plans for Biobank, CRAIN'S CLEVELAND Bus., Mar. 21, 2005, at 1; Dena
White, Banking the Future of Medicine, INSIDE (Duke Univ. Med. Ctr. & Health Sys.),
Mar. 7, 2005, available at http://inside.duke.edu/article.php?IssuelD=l 1 4&Parent
ID=9586&img=l.
800 [Vol. 51: p. 793
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sent from each of its patients within the two catchment areas covered by its
efforts before launching its personalized medicine project.2 3 Following
the example of the International HapMap Project 24 and the policies of the
Coriell Repositories, 25 some institutions are establishing community advi-
sory boards as well, which may serve simply as conduits of information
about the projects to the broader population or may play a more active
role in defining research questions and processes.
So why are some health care institutions not taking advantage of the
OHRP Guidance and HIPAA provisions to conduct research on clinical
records and samples without patient consent or IRB or public oversight?
One can only speculate because health care institutions rarely reveal their
innermost thoughts, but several hypotheses seem plausible. One is that
hospital legal counsel tends to be conservative, for good reason. This is a
hot topic. OHRP only recently clarified its position, after many years of
declining to provide guidance, 26 and the HIPAA privacy regulations are
an even more recent development. During the same period, numerous
commentators, 27 including scholars and patient advocates, argued that in-
formed consent should be required before clinical information and bio-
logical specimens are used for research. 28 Good lawyers, of course, can
23. Marshfield Clinic Research Found., Personalized Medicine Research Project,
http://www.marshfieldclinic.org/chg/pages/default.aspx?page=chg-pers-med-
resprj (last visited Feb. 9, 2006).
24. Int'l HapMap Consortium, Integrating Ethics and Science in the International
HapMap Project, 5 NATURE REvs. GENETICS 467 (2004).
25. Coriell Cell Repositories Home Page, http://locus.umdnj.edu/ccr/ (last
visited Feb. 11, 2006).
26. During the period when I was the chair of the CDC-NIH Working Group
on Informed Consent for Genetic Research on Stored Tissue Samples, we repeat-
edly asked the leadership of the Office of Protection from Research Risks (OPRR)
(the predecessor of the current Office of Human Research Protections) to provide
their views of these issues, which they repeatedly refused to do. Charles McCarthy,
long time Director of OPRR, told me in a subsequent conversation that this sort of
non-responsiveness was the policy of OPRR.
27. See, e.g., Lori B. Andrews, My Body, My Property, 16 HASTINGS CENTER REP.,
Oct. 1986, at 28 (arguing that body parts are akin to property, and thus donors, as
owners, must consent and receive compensation for use of their body parts); Laura
M. Beskow et al., Informed Consent for Population-Based Research Involving Genetics, 286
JAMA 2315 (2001) (advocating informed consent approach to genetic research);
Timothy Caulfield et al., DNA Databanks and Consent: A Suggested Policy Option In-
volving an Authorization Model, 4 BMC MED. ETHICS 1 (2003) (advocating "authori-
zation model" to research, allowing donors to exercise some control over uses of
their genetic data); Bartha Maria Knoppers & Claude Laberge, DNA Sampling and
Informed Consent, 140 CANADrAN MED. ASS'N J. 1023, 1023-28 (1989) (advocating
integrated approach to obtaining informed consent for DNA sampling); Schwartz
et al., supra note 17; Robert F. Weir & Jay R. Horton, DNA Banking and Informed
Consent-Part 1, IRB, July-Aug. 1995, at 1 (analyzing how informed consent re-
quirements are met by genetics investigators); Robert F. Weir & Jay R. Horton,
DNA Banking and Informed Consent-Part 2, IRB, Sept.-Dec. 1995, at 1 (proposing
that consent documents in genetics research address seven categories of consent).
28. Other commentators have argued that informed consent should not be
required prior to the use of tissue samples and medical records for research. See,
2006]
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look past commentary to see what the regulators are actually saying at pre-
sent, which is that there are no legal requirements in this area. And they
could take comfort in the knowledge that while someone could bring a
legal challenge to OHRP's interpretation of the regulations, overcoming
the deference given to the government's position would be a heavy
burden.
Ultimately, I suspect that the most important reason that health care
institutions are engaging in numerous forms of public involvement when
creating biobanks is not lack of awareness of the scope of the legal safe
haven, but rather the recognition that non-disclosure and lack of oversight
are risky in terms of public perception. It is hardly as if the American
public is universally enthusiastic about its hospitals and clinicians. The
health care system is under fire from a number of directions, from con-
cerns that too many people are falling through the cracks or being ban-
krupted to allegations of fiscal mismanagement, fraud and poor quality of
care. As part of this sea of concerns, health care institutions know that at
least some patients are concerned about how information about them and
specimens from them are used.29 They are all too aware that just one
person complaining to the media can create a fire storm. These entities
understand that what is needed is the public's trust and that this can be
achieved only through transparency and engagement with individuals and
communities. Ultimately, the silent creation of biobanks from clinical in-
formation and specimens turns out simply to be a bad idea, no matter
what the law says.
e.g., J. Cassell & A. Young, Why We Should Not Seek Individual Informed Consent for
Participation in Health Services Research, 28J. MED. ETHICS 313 (2002) (arguing that
informed consent requirements undermines mission of organizations conducting
research in interests of entire population); cf. Klaus Hoeyer et al., The Ethics of
Research Using Biobanks: Reason to Question the Importance Attributed to Informed Con-
sent, 165 ARcHWEs INTERNAL MED. 97, 97-100 (2005) (suggesting that informed
consent is inadequate measure of public acceptance of biobank-based research).
29. See supra notes 16-17 and accompanying text.
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